ReviewCurrent research in pharmacology and drug discovery2026
Therapeutic potential, pharmacological role and molecular mechanisms of adelmidrol, an analogue of palmitoylethanolamide.
Review in Current research in pharmacology and drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adelmidrol is a bioactive semi-synthetic compound with significant therapeutic potential, particularly in resolving inflammation since inflammation plays a key role in the pathogenesis of several diseases. The mechanisms of action of adelmidrol are multifaceted, involving interactions with specific receptors like the PPAR-γ and modulation of signaling pathways associated with inflammation. Adelmidrol demonstrates efficacy in conditions such as inflammatory bowel disease, colon inflammation, and urothelial inflammation by regulating the level of pro-inflammatory cytokines. In dermatological conditions like atopic and allergic dermatitis, adelmidrol plays a key role in modulating immune responses and enhancing skin barrier function by reducing inflammation while offering an alternative to conventional therapies. Additionally, adelmidrol plays a critical role in wound healing and diabetic foot ulcers by facilitating cell migration and proliferation, thus accelerating wound closure and reducing infection risk. Adelmidrol has been shown to reduce joint inflammation and improve functionality, making it a candidate for adjunct therapy in musculoskeletal disorders like osteoarthritis. The compound also addresses pulmonary conditions, such as pulmonary fibrosis, by mitigating inflammatory responses and improving respiratory function. Furthermore, applications of adelmidrol in liver diseases, including liver ischemia and non-alcoholic steatohepatitis (NASH), highlight its potential in resolving hepatic inflammation. This review emphasizes the therapeutic promise of adelmidrol across various inflammatory diseases, advocating for further clinical studies to establish its full potential and optimize its clinical use all the while providing an overview of the properties, mechanisms of action, and therapeutic applications of adelmidrol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.